THERAPY DOSSIER · th-54f978d2b9d5

Allogeneic bone marrow stromal cells (BMSC)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Haemorrhage/shock
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 7

3 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03003364 ↗Injury indicationPHASE1/PHASE2completed

Intrathecal expanded Wharton's jelly mesenchymal stem cells in chronic traumatic spinal cord injury

Spinal Cord Injury, Chronic

Enrolment: 10 · Results not recorded

NCT06981338 ↗Injury indicationPHASE1/PHASE2not yet recruiting

Intrathecal Wharton's jelly MSC plus transcutaneous spinal cord stimulation in chronic SCI

Spinal Cord Injuries

Enrolment: 10 · Results not recorded

NCT04288934 ↗Injury indicationPHASE1completed

Safety and effectiveness of bone marrow mesenchymal stem cells in spinal cord injury patients

Spinal Cord Injuries

Enrolment: 20 · Results not recorded

NCT03356821 ↗PHASE1/PHASE2completed

Adult mesenchymal stromal cells intranasally for neonatal arterial ischaemic stroke (PASSIoN)

Perinatal Arterial Ischemic Stroke · Neonatal Stroke

Enrolment: 10 · Results not recorded

NCT07371624 ↗PHASE1/PHASE2recruiting

Allogeneic adipose-derived mesenchymal stromal cell injection (B2065) in acute ischaemic stroke

Acute Ischemic Stroke

Enrolment: 54 · Results not recorded

NCT01922908 ↗PHASE1/PHASE2withdrawn

Safety of mesenchymal stromal cells for ischaemic stroke

Ischemic Stroke

Enrolment: 0 · Results not recorded

NCT03186456 ↗PHASE1suspended

Human umbilical cord-derived allogeneic MSC in acute cerebral infarction

Cerebral Infarction

Enrolment: 40 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21208021 ↗2011Reported benefit

Late transplantation of allogeneic bone marrow stromal cells improves neurologic deficits subsequent to intracerebral hemorrhage.

RatHaemorrhage/shockUnspecifiedWistarFemalen = 20Intralesional (intracerebral) injection5 x 10^6 cells2 months after haemorrhage (late)

Model: Intracerebral haemorrhage (stereotactic striatal injection of 0.5 IU collagenase type IV)

Late intracerebral allogeneic BMSC transplantation improved functional outcome and reactivated endogenous neurogenesis after intracerebral haemorrhage.

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…